Logo Logo Logo Logo Logo
  • Company


    • Company Overview


    • Board of Directors


    • Executive Team


    • Advisory Board
  • Pipeline


    • Product Overview


    • AR-301 (Salvecin®)


    • AR-101 (AerumabTM)


    • AR-501 (Panaecin™)


    • AR-712 (COVID-19 mAb)


    • AR-701 (COVID-19 mAb)

    • Preclinical


      • AR-401

    • Out-licensed Products


      • AR-105 (Aerucin®)


      • AR-201
  • TECHNOLOGY


    • Technology Overview


    • ʎPEXTM


    • MabIgX®


    • Therapeutic Targets


      • HAP / VAP


      • Cystic Fibrosis


      • COVID-19 Disease
  • Investors


    • Welcome


    • Corporate Governance


      • Board of Directors


      • Board Committees


    • News Releases


    • SEC Filings


    • Stock Information


      • Interactive Chart


      • Investment Calculator


      • Historical Stock Price


      • Analyst Coverage


    • Events and Webcasts


    • Publications and Posters


    • Investor Alerts


    • Investor Inquiries
  • Contact Us


    • Contact Us


    • Careers
  • Company


    • Company Overview


    • Board of Directors


    • Executive Team


    • Advisory Board
  • Pipeline


    • Product Overview


    • AR-301 (Salvecin®)


    • AR-101 (AerumabTM)


    • AR-501 (Panaecin™)


    • AR-712 (COVID-19 mAb)


    • AR-701 (COVID-19 mAb)

    • Preclinical



      • AR-401

    • Out-licensed Products



      • AR-105 (Aerucin®)


      • AR-201
  • TECHNOLOGY


    • Technology Overview


    • ʎPEXTM


    • MabIgX®


    • Therapeutic Targets



      • HAP / VAP


      • Cystic Fibrosis


      • COVID-19 Disease
  • Investors


    • Welcome


    • Corporate Governance


      • Board of Directors


      • Board Committees


    • News Releases


    • SEC Filings


    • Stock Information


      • Interactive Chart


      • Investment Calculator


      • Historical Stock Price


      • Analyst Coverage


    • Events and Webcasts


    • Publications and Posters


    • Investor Alerts


    • Investor Inquiries
  • Contact Us


    • Contact Us


    • Careers
Search:
 



Sitemap

COMPANY

  • Overview
  • Board of Directors
  • Executive Team 
  • Advisory Board

 

PIPELINE

  • Overview
  • AR-301 (Salvecin®)
  • AR-101 (AerumabTM)
  • AR-501 (PanaecinTM)

 

PRECLINICAL

  • AR-201
  • AR-401

 

TECHNOLOGY

  • Overview
  • MabIgX®

 

THERAPEUTICS TARGETS

  • HABP / VABP
  • Cystic Fibrosis

 

NEWS & EVENTS

  • Press Releases
  • Events

 

INVESTORS + MEDIA

  • Publications
  • Email Alerts

 

Contact Us

CONTACT US

Aridis Pharmaceuticals Inc.
983 University Avenue, Bldg. B
Los Gatos, CA 95032
Phone: 408-385-1742
Fax: 408-356-9548

 

 

ADDITIONAL INFORMATION

Site Map
Privacy Policy
Financial Conflict of Interest Policy

RSS News Releases
  • Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of a Second Inhaled Antibody to Neutralize Newly Emerging COVID-19 Mutated Variants February 23, 2021
  • Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020 November 24, 2020
  • Aridis Pharmaceuticals Announces Third Quarter 2020 Results November 20, 2020